Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg, Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure.

Trial Profile

Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg, Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2013

At a glance

  • Drugs Torasemide (Primary) ; Furosemide
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Sponsors Ferrer
  • Most Recent Events

    • 26 May 2012 New source identified and integrated: Clinical Trials Database record EudaCT2011-000972-32.
    • 15 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top